Status:
COMPLETED
Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age
Lead Sponsor:
Sanofi
Conditions:
Japanese Encephalitis
Eligibility:
All Genders
9-10 years
Phase:
PHASE2
Brief Summary
This randomised, double-blind study is to be conducted on 96 subjects at multiple sites in India. Subjects will be enrolled by age group and randomised to either ChimeriVax™-JE (JE-CV) or JE Mouse Bra...
Eligibility Criteria
Inclusion
- All aspects of the Protocol explained and written informed consent obtained from the subject's parent or guardian and assent from the child if ≥ 8 years of age.
- Aged ≥ 9 months to \< 10 years
- In good general health, without significant medical history, physical examination findings, or clinically significant abnormal laboratory results
- Subject had to be available for the study duration for the study duration, including all planned follow-up visits.
Exclusion
- A history of vaccination against, or infection with, JE or other flaviviruses (e.g. Kyanasur Forest Disease, West Nile virus, dengue fever). Previous JE vaccination was to be determined by history (interview of subject's parent or guardian) or by inspecting the child's official vaccination record.
- Demonstration of parasitemia on malaria blood smear at Screening.
- History of residence in or travel to a JE-endemic region of India or elsewhere in Asia (for periods of 4 weeks or more).
- hypersensitivity to thimerosal or gelatin
- Have received a transfusion of blood, blood products or serum globulin in the preceding 6 months,
- Have an immunodeficiency or neurological disorder, or take drugs that suppress the immune system,
- Have a history of severe reaction to other vaccines,
- Have a chronic condition requiring medication,
- Intend to travel out of the area during the study period,
- Have spent at least 4 weeks in a JE-endemic region,
- Plan to receive any other vaccination within the double-blind treatment period, or who have received a vaccination in the month preceding Screening,
- Exhibit signs of secondary or tertiary malnutrition,
- Are seropositive to human immunodeficiency virus (HIV), Hepatitis B or C,
- Have malaria infection, or who have a fever within 3 days before vaccination.
- Those with an acute fever, or with previously scheduled vaccinations, may be rescheduled.
- Consideration of the routine immunisation schedule should be made such that it is ensured that routine vaccinations due are either given before entry to the trial, or afterwards if delayed because of the trial.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT00441259
Start Date
January 1 2007
End Date
December 1 2011
Last Update
August 27 2012
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr Atul's Child Hospital
Jaipur, Rajasthan, India, 302016
2
Government Medical College
Baroda, India, 390001
3
Maulana Azad Medical College
New Delhi, India, 110002